H1

Medical affairs teams are shifting priorities, focusing on quality engagements over quantity. But how do you maximize the impact of these strategic interactions? For Jennifer Wheeler, Associate Director of Analytics at Johnson & Johnson, comprehensive data from H1 has been crucial. In our latest interview, Jennifer shares how H1's data empowers J&J to: ✓ Optimize medical education planning ✓ Build diverse advisory boards with new experts ✓ Enhance clinical trial diversity See how H1's breadth of data is driving true medical affairs innovation. Watch the full interview: https://hubs.la/Q038n0ky0

February is #AmericanHeartMonth and according to the American Heart Association, approximately 1/4 of all U.S. adults have high LDL-C, which contributes to millions of deaths each year. With #heartdisease impacting so many lives, it’s critical for all patients to follow HCP recommendations for prevention and detection. According to our internal data, we see procedure counts related to heart disease decreasing by roughly 20% over the past 5 years. Some reasons that may have contributed to this shift are: 💡 Downstream impacts from COVID-19 💡 An increase in medical device usage To help address increasing challenges with care delivery and a constantly changing diversity landscape, H1 offers all of the granular diversity data you need to support all patient populations. Learn more: https://hubs.la/Q037CXmQ0 *Data sourced from the H1 platform

Are you curious how leading pharma companies like Johnson & Johnson are innovating their medical affairs strategies? From building diverse advisory boards to uncovering care gaps and enhancing clinical trial diversity - the landscape is rapidly evolving. In an exciting upcoming interview, our own Stacey Rivkin speaks with Jennifer Wheeler, Associate Director of Analytics at J&J, about how comprehensive data insights are transforming their approach. Jennifer shares best practices for optimizing medical education, identifying new experts beyond traditional KOLs, and more. Keep an eye out as we share the interview later this week!

In an effort to address disparities in health outcomes for #prostatecancer patients, Novartis is contributing to a project that hopes to save 100,000 lives by 2035. Nonprofit organization ZERO Prostate Cancer aims to tackle care barriers for Black men, veterans, and rural underserved communities with its Blitz the Barriers initiative. These demographic groups are more likely to be diagnosed with prostate cancer and face typically worse outcomes than the rest of the general population. Learn more about how Novartis has committed to this educational outreach campaign: https://hubs.la/Q037lJ510

Most of us have a certain routine that helps us settle into each workday: checking emails, skimming news sites, opening our calendars. For Sheila Komara, it’s digging into her morning alerts from H1. As a Sr. Medical Science Liaison at Jazz Pharmaceuticals, Sheila relies on seeing publication and social media alerts about the #KOLs she engages with. Seeing their actions in real-time allows her to keep track of what they’re focused on day-to-day and to touch base with them about their activities and successes. Learn more about how H1 has enhanced her practice as a seasoned #MSL: https://hubs.la/Q034Ly420

#ICYMI We recently shared how our H1 Connect team supported humanitarian organization Team Rubicon by finding cholera experts to join a deployment in response to a major outbreak in Zambia. See how we were able to quickly find relevant experts to support Team Rubicon's clinical support mission. Download the case study: https://hubs.la/Q036QWft0

If there are any concepts in healthcare that qualify as buzzwords, “patient-centric” is certainly one of them. But there’s good reason for that since so many healthcare professionals get into their fields because of a very real passion for improving patient care. Sheila Komara is no exception and it was clear from speaking with her how much she values keeping patients at the forefront of her work. Her role as a Sr. Medical Science Liaison at Jazz Pharmaceuticals enables her to work closely with KOLs to better understand the patient experience and to help get potentially life-changing medications into the hands of the patients who need them. Watch the full interview to see how H1 supports her mission: https://hubs.la/Q036PkkN0

Last month, we were honored to have our CEO Ariel Katz join a VIP Leadership Roundtable at the World Economic Forum #davos to discuss “Combating Hate and Indifference and Promoting Positive Action.” With the steep rise in antisemitic incidents in recent years, as reported by the Anti-Defamation League, there is a need to address the impact on Jewish employees and the growing indifference toward these issues. The group talked about the role that leaders play in addressing these problems and committed to actionable steps they can take within their own organizations to ensure all employees feel valued, empowered, and connected. Thank you to everyone who participated in this important and timely conversation!

On this #PresidentsDay, we celebrate the dedication and leadership of those who have served as president since our country’s founding. Leadership, service and resilience are just a few of the values that define our democracy. Today we celebrate the opportunities our nation offers and continue to work toward a bright future.

Earlier this week, Roche was granted FDA approval for Evrysdi, the first-ever tablet to treat spinal muscular atrophy (SMA). The approval makes Evrysdi the only noninvasive disease-modifying therapy for SMA, according to Roche. The tablet will be available in the coming weeks and offers a more convenient option for patients. Learn more: https://hubs.la/Q036DSdw0 #spinalmuscularatrophy #sma #roche #genentech #evrysdi